tbuckley/cabot-search huggingface dataset:
P0624 : Acute viral hepatitis: Epidemiological change during the last 25 years in Spain
Authors: M. Riveiro-Barciela, E. Mena, S. Romero, M. Ventura-Cots, J. Llaneras, F. Rodríguez-Frias, R. Esteban, M. Buti
Journal: Journal of Hepatology (2015)
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it.
Authors: I. Sestak, M. Harvie, A. Howell, J. F. Forbes, M. Dowsett, J. M. Cuzick
Journal: Journal of Clinical Oncology (2011)

165 Background: Weight gain is commonly reported by patients with breast cancer. Aromatase inhibitors are being tested in the preventive setting in high risk women and it is important to evaluate the association between treatment and weight change as this may effect the patient’s decision to continue to take the drug. Methods: Weight change in postmenopausal women from three large clinical trials (ATAC, IBIS-I, IBIS-II) investigating endocrine treatment for the treatment and prevention of breast cancer have been analysed. The objective of this retrospective study was to assess the effects of anastrozole and tamoxifen on weight change in postmenopausal women. Results: In the ATAC trial, a mean increase of 1.4 kg was observed after 12 months of follow-up and no statistically significant differences between treatment arms (anastrozole vs. tamoxifen) were found. The majority of women kept their weight stable and only 11.2% gained more than 5 kg within this time period. Significant baseline predictors for gaining more than 5 kg of weight after 12 months of follow-up were being younger than 60 years old at entry, smoking at entry, and mastectomy. Results for the two prevention studies IBIS-I and IBIS-II were quite similar. In the IBIS-II trial, the overall mean weight change after 12 months of follow-up was 0.5 kg. In the IBIS-I study women gained an average of 0.9 kg within the first 12 months of follow up. In both studies no differences between treatment and placebo (IBIS-I: tamoxifen vs. placebo; IBIS-II: anastrozole vs. placebo) were observed. Overall, women in the adjuvant setting gained more than 5 kg of weight (11.2%) after 12 months of follow up compared to those in the preventive setting (5.3% IBIS-I, 5.7% IBIS-II), but similar overall weight gain was seen after 60 months of follow up in both settings (5.7% IBIS-I vs. 6.1% ATAC). Conclusions: All three trials have demonstrated that weight gain occurs primarily within the first 12 months of active treatment and are similar to those on placebo. Weight stabilises after 12 months of follow up and major weight gain was rare in all trials, and unrelated to treatment.
High-dose chemotherapy plus autologous stem cell transplation (HDCT/ SCT) in patients with sarcoma: A single institution experience.
Authors: A. Stradella, A. Lopez-Pousa, M. J. Quintana, P. Murata, M. Ortin, O. Gallego, I. Sullivan, L. Robert, A. Sebio, I. Gracia, J. M. De Vega, A. Barnadas
Journal: Journal of Clinical Oncology (2011)

10042 Background: Chemotherapy is the standard treatment in high risk advanced sarcomas. The role of HDCT/SCT is controversial in this patients (pt). We described our experience and long term results in sarcoma patients treated into a compassionate use program. Methods: From 12/1988 to 09/2007, 22 pt (16 male, 6 female) with advanced undifferentiated round cell soft tissue or bone sarcoma (15 (68%) Ewing S, 7 (32%) rhabdomyosarcoma) underwent HDCT/SCT; 10 pt had advanced locoregional sarcomas, 12 pt metastatic disease at onset.A minimum of 4x106 CD34+/kg cells were collected. 18 pt received conditioning HDCT regimen with (cyclophosphamide 1500 mg/m2, carboplatin 350 mg/m2, etoposide 400 mg/m2) iv x 3 d.; In 4 pt treated with double HDCT/SCT (tandem), conditioning was ifosfamide 2,500 mg/m2, carboplatin 360 mg/m2, etoposide 310 mg/m2 iv × 4 d. Only pts with CR and maximum PR to previous treatments were included (17 RC, 5 PR). One PR pt was included with an early progression before 1st ASCT. Eighteen pt received HDTC as 1st line treatment, 4 pt in recurrent disease. Previous treatment included CT (VAC-IE, others), surgery and/or RT. Results: Median follow-up was 39,8 m. Median age: 22 years (17 – 34); Post-HDCT/SCT all pt developed toxicity: grade (G) 4 hematologic, G 3-4 gastrointestinal, neutropenic fever. Severe venooclusive disease in 2. Two pt transplant-related death. After SCT 16 pt (80%) were CR, 1 (5%) PR, and 3 (15%) PD. The median PFS was 18.4 m (95%CI: 13.3-23.5). Median OS was 35 m (95% CI: 0-137). In the univariate analysis, PFS was significant according to sex (men: 18 vs 3m, p= 0.05) and complete response to HDCT (30m vs 3m, p= 0.002), and remains independent factors in the multivariate analysis. Age, histology and response to previous treatment showed a trend towards significance. Complete response to HDCT was the only independent significant factor for OS (143.5m vs 7.8m, p= 0.002). Conclusions: HDCT is feasible without long term toxicities in this series. Disease response to HDCT was the best predictor for survival. Out of clinical trial, this treatment should not be considered an standard treatment, although it could be an option in selected patients.
Know when to say when: Serial assessment of apoptosis and lymphocyte infiltrates with combined intraprostatic autologous dendritic cell immunotherapy/radiation therapy in high-risk prostate cancer.
Authors: S. E. Finkelstein, D. Gabrilovich, F. A. Rodriguez, T. Chuang, L. Kang, J. Torres-Roca, R. Heysek, J. M. Pow-Sang, S. Antonia, M. N. Fishman
Journal: Journal of Clinical Oncology (2011)

149 Background: Previous work suggested combining local radiotherapy (XRT) with intratumoral syngeneic dendritic cell (DC) injection could result in apoptosis/cell death mediated induction of cytotoxic T lymphocytes (CTL) based anti-tumor immunity. However, the presence, timing, and effectiveness of effector CTL prior, during, and following combined XRT/intratumoral autologous DC injection in humans is unknown. Methods: Herein, we report on timing concerns of intraprostatic DC injection in vivo, in human; five HLA-A2+, high risk localized prostate cancer patients were treated on protocol using androgen suppression therapy (AS), external beam radiation therapy (EBRT, 45 Gy) followed by brachytherapy permanent interstitial implant with addition of autologous intraprostatic DC injections during EBRT, after fractions 5, 15, and 25 of 25. Multiple serial prostate biopsies were collected before initiation of treatment, during EBRT and at 3, 12, 24 and 36 months after completion of treatment. Biopsies were stained for CD3, CD4, CD8, and cleaved caspase 3, and evaluated in a blinded manner. Specific anti-tumor immunity was assessed via ELISpot IFN-gamma production by CTL stimulated by HLA-A2 peptides derived from sequences of proteins associated with prostate cancer. Results: Apheresis, DC injections, and biopsies were well tolerated. The pattern of distribution of CD8+ cells was consistent with prostate cancer antigen targeting, rather than non-specific organ infiltration. There was not immediate obvious intraprostratic infiltrate by CTL after DC injection in vivo, in humans. Measurable, induced increases in ELISpot titers in peripheral blood CTL were observed for some subjects and for some antigens, but non-specific immunity fluctuated. Conclusions: This initial translational experience demonstrates safety and timing of DC injection coordinated with combined AS and XRT. Design of future trials employing combination XRT and DC will consider timing concerns to match therapy-induced apoptosis/cell death. No significant financial relationships to disclose.
Transient Elastography (FibroScan®) for Noninvasive Assessment of Liver Amyloidosis.
Authors: Arnaud Jaccard, Anne Cypierre, Annick Rousseau, Fatima Yagoubi, Julie Abraham, Annie Lefebvre, Elisabeth Vidal, Dominique Bordessoule, Véronique Loustaud-Ratti
Journal: Blood (2009)
Combined High Resolution Genomic and Expression Profiles Microarray Analysis in Sezary Syndrome.
Authors: Elisabetta Caprini, Cristina Cristofoletti, Diego Arcelli, Paolo Fadda, Mauro Helmer Citterich, Francesca Sampogna, Armando Magrelli, Paola Torreri, Federica Censi, Marina Frontani, Enrico Scala, Maria Cristina Picchio, Alessandro Monopoli, Giuseppe Alfonso Lombardo, Domenica Taruscio, Maria Grazia Narducci, Giandomenico Russo
Journal: Blood (2009)
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial
Authors: Ganesh Raghu, Kevin K Brown, Harold R Collard, Vincent Cottin, Kevin F Gibson, Robert J Kaner, David J Lederer, Fernando J Martinez, Paul W Noble, Jin Woo Song, Athol U Wells, Timothy P M Whelan, Wim Wuyts, Emmanuel Moreau, Scott D Patterson, Victoria Smith, Selina Bayly, Jason W Chien, Qi Gong, Jenny J Zhang, Thomas G O'Riordan
Journal: The Lancet Respiratory Medicine (2016)
Potential Therapeutic Intervention Suggested by Profound Deficiency of Neutrophil-Derived Bactericidal/Permeability-Increasing Protein (BPI) and Other Alterations in LPS-Directed Innate Immunity after Myeloablative Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Ofer Levy, Eugenie E. Suter, Leslie A. Kalish, Janice Russell, Patrick Scannon, Eva C. Guinan
Journal: Blood (2006)
Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation
Authors: Jennifer E. Posey, Tamar Harel, Pengfei Liu, Jill A. Rosenfeld, Regis A. James, Zeynep H. Coban Akdemir, Magdalena Walkiewicz, Weimin Bi, Rui Xiao, Yan Ding, Fan Xia, Arthur L. Beaudet, Donna M. Muzny, Richard A. Gibbs, Eric Boerwinkle, Christine M. Eng, V. Reid Sutton, Chad A. Shaw, Sharon E. Plon, Yaping Yang, James R. Lupski
Journal: New England Journal of Medicine (2016)

Whole-exome sequencing can provide insight into the relationship between observed clinical phenotypes and underlying genotypes.We conducted a retrospective analysis of data from a series of 7374 consecutive unrelated patients who had been referred to a clinical diagnostic laboratory for whole-exome sequencing; our goal was to determine the frequency and clinical characteristics of patients for whom more than one molecular diagnosis was reported. The phenotypic similarity between molecularly diagnosed pairs of diseases was calculated with the use of terms from the Human Phenotype Ontology.A molecular diagnosis was rendered for 2076 of 7374 patients (28.2%); among these patients, 101 (4.9%) had diagnoses that involved two or more disease loci. We also analyzed parental samples, when available, and found that de novo variants accounted for 67.8% (61 of 90) of pathogenic variants in autosomal dominant disease genes and 51.7% (15 of 29) of pathogenic variants in X-linked disease genes; both variants were de novo in 44.7% (17 of 38) of patients with two monoallelic variants. Causal copy-number variants were found in 12 patients (11.9%) with multiple diagnoses. Phenotypic similarity scores were significantly lower among patients in whom the phenotype resulted from two distinct mendelian disorders that affected different organ systems (50 patients) than among patients with disorders that had overlapping phenotypic features (30 patients) (median score, 0.21 vs. 0.36; P=1.77×10-7).In our study, we found multiple molecular diagnoses in 4.9% of cases in which whole-exome sequencing was informative. Our results show that structured clinical ontologies can be used to determine the degree of overlap between two mendelian diseases in the same patient; the diseases can be distinct or overlapping. Distinct disease phenotypes affect different organ systems, whereas overlapping disease phenotypes are more likely to be caused by two genes encoding proteins that interact within the same pathway. (Funded by the National Institutes of Health and the Ting Tsung and Wei Fong Chao Foundation.).
Severe acute respiratory infection caused by swine influenza virus in a child necessitating extracorporeal membrane oxygenation (ECMO), the Netherlands, October 2016
Authors: Pieter L A Fraaij, Enno D Wildschut, Robert J Houmes, Corien M Swaan, Christian J Hoebe, H C C de Jonge, Paulien Tolsma, Isme de Kleer, Suzan D Pas, Bas B Oude Munnink, My V T Phan, Theo M Bestebroer, R Shanty Roosenhoff, Jeroen J A van Kampen, Matthew Cotten, Nancy Beerens, Ron A M Fouchier, Johannes H van den Kerkhof, Aura Timen, Marion P Koopmans
Journal: Eurosurveillance (2016)

In October 2016, a severe infection with swine influenza A(H1N1) virus of the Eurasian avian lineage occurred in a child with a previous history of eczema in the Netherlands, following contact to pigs. The patient’s condition deteriorated rapidly and required life support through extracorporeal membrane oxygenation. After start of oseltamivir treatment and removal of mucus plugs, the patient fully recovered. Monitoring of more than 80 close unprotected contacts revealed no secondary cases.
Radical prostatectomy (RP) in extreme ages: Clinical and pathologic evaluation of localized prostate cancer (PC).
Authors: A. A. Dettino, F. P. Fonseca, S. C. Zequi, C. A. Sacomani, J. Rinck, N. Formiga, A. Lopes
Journal: Journal of Clinical Oncology (2011)

109 Background: Radical prostatectomy (RP) is the treatment of choice for patients with localized prostate cancer (PC). Previously, surgery was applied to patients with good clinical condition and aged &lt;=70 years. Lately, with a better understanding of surgical technique, many centers have been performing RP in patients older than 70. Methods: The main objective of this cohort study is to evaluate clinical evolution according to localized PC submitted to RP in patients in extreme ages. We analysed age, PSA, ASA classification,pathological stages, Gleason scores, urinary continence, D'Amico risk classification (group 1:low; 2:intermediate; 3:high), biochemical recurrence and clinical progression. Descriptive analysis of the population was performed. Fisher's exact test or chi-square tests were used to evaluate association between clinicopathologic characteristics.Biochemical recurrence was defined by PSA more than 0.2 ng/mL post-RP. Results: In 262 patients, mean age was 63.4 years (SD 12.4; range: 41 to 83). In D'Amico's group 1 there were 96 patients (37.2%) with&lt;=50 year old, and group 2 had 162 patients (62.8%) with age &gt;=70. The mean follow-up in group 1 was 55.9 months (SD 41.7) and group 2 was 53.6 (SD 41.4), p=0.6770. Biochemical relapse occurred in 21 patients (15.44%) in D'Amico risk group 1, 27 (36.99%) in group 2 and 29 (59.18%) in group 3 (p&lt;0.001). There was no difference among all the pathological variables evaluated (p&gt;0.05). Clinical progression occurred in 2 patients (1.47%) in D'Amico risk group 1, in 3 patients (4.11%) in group 2 and in 3 patients (6.11%) in group 3 (p=0.230). There was no significant difference in relation to time to biochemical recurrence, as well as biochemical relapse rate and progression of this disease among the groups. Younger patients (in group 1) recovered earlier from urinary incontinence, as well as most were continent in final follow-up. Conclusions: Based on our results, the differences in younger or more aged patients with PC are not related to pathological variables, or rates of biochemical recurrence and clinical disease, but better preoperative clinical features and better recovery of urinary continence are seen in younger patients. No significant financial relationships to disclose.
A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study
Authors: Thomas Prebet, Jacques Delaunay, Eric Wattel, Thorsten Braun, Pascale Cony-Makhoul, Sophie Dimicoli, Stefan Wickenhauser, Julie Lejeune, Sylvie Chevret, Fatiha Chermat, Pierre Fenaux, Norbert Vey
Journal: Blood (2015)
A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer.
Authors: Donald Anthony Richards, Joe Stephenson, Brian M. Wolpin, Carlos Becerra, John Turner Hamm, Wells A. Messersmith, Shannon Devens, Jill Cushing, Tess Schmalbach, Charles S. Fuchs
Journal: Journal of Clinical Oncology (2012)

213 Background: IPI-926 is a novel, natural product-derived small molecule that targets the Hedgehog (Hh) pathway by inhibiting smoothened. In preclinical models of pancreatic cancer, repressing activation of the Hh pathway diminishes tumor-associated desmoplasia and improves chemotherapy delivery. Methods: This is the final report of the Phase 1b portion of a Phase 1b/2 trial evaluating the safety and efficacy of IPI-926 plus gemcitabine. Eligible patients (pts) with untreated metastatic pancreatic cancer and ECOG status 0-1 were administered oral IPI-926 daily (QD) for 28-day cycles, in 3 to 6 pt dose cohorts. Gemcitabine (1,000 mg/m 2 ) was administered IV weekly for 3 weeks with 1 week off. DLTs were evaluated during Cycle 1. Results: 16 pts (median age 69 years; range 58-86) were enrolled at IPI-926 doses of 110, 130 or 160 mg QD (single agent MTD). Pts received a median of 5 cycles (1-13). Two pts remain on trial. No IPI-926-related serious AEs have been observed. One DLT of Grade 3 AST increase was observed (130 mg dose cohort) and was asymptomatic; it resolved with dose interruption, and did not recur with dose reduction. The most common AEs occurring were fatigue (75% total, 6% ≥ Grade 3), thrombocytopenia (63%, 25%), anemia (56%, 13%), nausea (50%, 0%), diarrhea (44%, 0%), vomiting (44%, 0%), peripheral edema (44%, 0%), pyrexia (44%, 0%), and AST increase (44%, 13%). Dose reductions of IPI-926 occurred in 3 (19%) pts. Dose reductions of gemcitabine occurred in 11 (69%) pts, primarily for thrombocytopenia (9 pts). One pt (6%) discontinued due to an AE (microangiopathic hemolytic anemia). Five (31%) radiographic partial responses were observed (1/3 at 110 mg, 2/6 at 130 mg, 2/7 at 160 mg). Median progression-free survival is &gt; 7 months. 74% of pts were alive 6 months after study entry. Conclusions: IPI-926 plus gemcitabine is well tolerated in pts with untreated metastatic pancreatic cancer, with evidence of activity and no unexpected toxicity. Complete Phase 1b data, including final overall survival, will be presented. Clinical evaluation of this combination continues in the randomized, double-blind, placebo-controlled Phase 2 portion of the trial.
Estimating the Annual Volume of Hematologic Cancer Cases per Hematologist-Oncologist in the United States: Are We Treating Rare Cancers Too Rarely?
Authors: Aishwarya Ravindran, Wilson I. Gonsalves, Shahrukh K. Hashmi, Prashant Kapoor, Ariela L. Marshall, Mustaqeem A. Siddiqui, Ronald S. Go
Journal: Blood (2015)
The Studies in Various Murine Strains with Defects in Activation of Complement Cascade (CC) Reveal Both Pivotal and Pleiotropic Role of CC in Mobilization of Hematopoietic Stem/Progenitor Cells.
Authors: Marcin Wysoczynski, Ryan Reca, Wu Wan, Magda Kucia, Marina Botto, Janina Ratajczak, Mariusz Z. Ratajczak
Journal: Blood (2007)
The Kinase Inhibitor Sorafenib Can Disrupt the Survival Support Provided by the Microenvironment and Induce Apoptosis of Chronic Lymphocytic Leukemia Cells
Authors: Jessie-F Fecteau, Ila Bharati, Morgan O'Hayre, Tracy Handel, Thomas J. Kipps, Davorka Messmer
Journal: Blood (2010)
Bacillus cereus-induced food-borne outbreaks in France, 2007 to 2014: epidemiology and genetic characterisation
Authors: Benjamin Glasset, S. Herbin, L. Guillier, S. Cadel-Six, M. Vignaud, J. Grout, S. Pairaud, V. Michel, J. Hennekinne, Nalini Rama Rao, A. Brisabois
Journal: Eurosurveillance (2016)

The aim of this study was to identify and characterise Bacillus cereus from a unique national collection of 564 strains associated with 140 strong-evidence food-borne outbreaks (FBOs) occurring in France during 2007 to 2014. Starchy food and vegetables were the most frequent food vehicles identified; 747 of 911 human cases occurred in institutional catering contexts. Incubation period was significantly shorter for emetic strains compared with diarrhoeal strains A sub-panel of 149 strains strictly associated to 74 FBOs and selected on Coliphage M13-PCR pattern, was studied for detection of the genes encoding cereulide, diarrhoeic toxins (Nhe, Hbl, CytK1 and CytK2) and haemolysin (HlyII), as well as panC phylogenetic classification. This clustered the strains into 12 genetic signatures (GSs) highlighting the virulence potential of each strain. GS1 (nhe genes only) and GS2 (nhe, hbl and cytK2), were the most prevalent GS and may have a large impact on human health as they were present in 28% and 31% of FBOs, respectively. Our study provides a convenient molecular scheme for characterisation of B. cereus strains responsible for FBOs in order to improve the monitoring and investigation of B. cereus-induced FBOs, assess emerging clusters and diversity of strains.
Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant
Authors: Ruth Pettengell, Norbert Schmitz, Christian Gisselbrecht, Graeme Smith, William N Patton, Bernd Metzner, Dolores Caballero, Herve Tilly, Jan A Walewski, Isabelle Bence-Bruckler, Bik To, Christian H. Geisler, Rik Schots, Eva Kimby, Christian J. Taverna, T. Kozak, Ruzena Uddin, Carmen Ruiz de Elvira, Anthony H. Goldstone
Journal: Blood (2010)
The Antileukemic Potential of New Derivatives of 5-Fluoro-1H-Indole-2,3-Dione-3-Thiosemicarbazone on in Vitro Cell Lines
Authors: Serap Erdem Kuruca, Nilgun Karali, Beyza Cetin, Sabriye Karadenizli, Zeynep Karakas
Journal: Blood (2008)
Phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder.
Authors: U. B. Chaudhary, A. R. Golshayan, A. Brisendine, A. S. Kraft, H. Clarke, T. E. Keane
Journal: Journal of Clinical Oncology (2011)

276 Background: Cisplatin-based neoadjuvant chemotherapy has shown survival advantage in patients (pts) with muscle-invasive bladder cancer. This benefit is strongly associated with downstaging of tumor to pT0. It was hypothesized that the addition of antiangiogenic therapy bevacizumab (Avastin [A]) to cisplatin (C) and gemcitabine (G) chemotherapy may offer improved outcomes in these pts. Methods: Patients with clinically localized, muscle-invasive, chemotherapy-naive TCC of bladder (T2-T4a), ECOG PS 0-1 received cisplatin 70 mg/m 2 IV day 1, gemcitabine 1000 mg/m 2 IV day 1 and 8, bevacizumab 15 mg/kg IV day 1 on a 21- day cycle for up to 4 cycles. After completion of neoadjuvant therapy all pts underwent RC. Those pts not achieving pT0 status received paclitaxel 175 mg/m2 IV day 1 and bevacizumab 15 mg/m 2 IV day 1 on a 21-day cycle for up to 3 cycles. The primary objective of the trial was to achieve pT0 status. Results: By October 2010, 15 pts were enrolled, and 13 are evaluable for response. Median age was 64 (range 47-71), 9 (70%) males, 4 (30%) females. 2/13 (15%) developed PD after neo-adjuvant therapy and were taken off protocol.11/13 (85%) underwent RC. 4/13 (31%) pts were downstaged, 3/11 (27%) achieved pTis status and none achieved pT0 status. 2/11 (18%) pts received adjuvant paclitaxel chemotherapy with bevacizumab. Dose reduction or delays were noted in 12/15 (80%) pts. Grade 3 or 4 hematologic toxicity was observed in 5/15 (33%) pts. Grade 3 or 4 nonhematologic toxicity was observed in 3/15 (20%) pts: (renal dysfunction 2 pts, pulmonary embolism 1 pt). Postoperative complications were seen in 5/12 (42%) pts: enterovesicular fistula (1), delayed wound healing (1), prolonged ileus (2), and pelvic abscess (1). With a median follow-up time of 12 months (range 3-45), 8/11 (72%) pts have remained disease free. Conclusions: Neoadjuvant CGA is feasible in pts with clinically localized, muscle-invasive TCC of the bladder. The surgical complications rate appears rather high and close monitoring is needed. Accrual to the trial continuous and updated results will be presented. No significant financial relationships to disclose.